Clarivate (NYSE:CLVT) was downgraded by analysts at The Goldman Sachs Group, Inc. to a "neutral" rating.
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report [Yahoo! Finance]
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report [Globe and Mail, The (Toronto, Canada)]